

Freedom of Information Request	FOI 21-178	18 th May 2021
--------------------------------	------------	---------------------------

I am researching the use of biologic products in respiratory medicine. Could you please provide answers to the following questions:

Q1. How many patients have been treated for severe asthma (ICD10 code J45.5) in the last three months?

• **Total patients**

70

• **Patients aged 6-11 years**

6

• **Patients aged 12-17 years**

2

• **Patients aged 18 years and above**

56

Please note that there is no such ICD10 code as J45.5, so data has been provided for all patients discharged with a primary diagnosis of asthma.

Q2. How many patients have been treated (for any condition) in the last three months with:

The Health Board is only able to supply information by quantity and not by the number of patients treated. The items dispensed below are for the period 1st February 2021 to 30th April 2021 for respiratory:

• **Benralizumab 30mg in 1 ml PF Pen = 14**

• **Omalizumab 150mg PF Syringe = 658**

• **Omalizumab 75mg PF Syringe = 57**

• **Reslizumab = 0**

• **Mepolizumab 100mg/ml PF Pen = 137**

• **Mepolizumab 100mg/ml PF Syr = 4**

Q3. How many patients have been treated in the last three months for asthma ONLY with:

• **Dupilumab**

• **Upadacitinib**

The Health Board does not hold a register and would have to review every patient record to determine this. Therefore in order to comply with your request the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.